New test detects residual cancer DNA in the blood without relying on tumor data
After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Dr. Parikh is an expert in Gastrointestinal Cancers with a focus on Young Adults with Colorectal Cancer and also see patients with Pancreatic Cancer. She sits on the NCCN guidelines committee for Colorectal Cancer. She leads many of the clinical trials in the GI GI oncology for patients with Colorectal and Pancreatic Cancer and brings novel agents into the clinic. She works closely with several labs including the Corcoran and Ting labs at the MGH Cancer Center who study colorectal and pancreatic cancers. She also leads the liquid biopsy efforts for the GI Oncology group and is an international expert in liquid biopsies helping to develop these tools in the setting of residual disease after curative intent surgeries, to understand response to treatment as well as to understand drug resistance. Though she is a clinical translational researcher, she also has a passion and background in cancer care in low and middle-incomes countries and does work that supports access, equity and education in LMICs.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
Languages:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and recognized in 14 specialties assessed by U.S. News & World Report.
After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence.
Research at the MGH is interwoven throughout more than 30 departments, centers and units, and is conducted with the support and guidance of the MGH Research Institute. The Research Roundup is a monthly series highlighting studies, news and events.
Researchers have developed a method to design drugs that efficiently block rather than activate critical cell receptors which may help avoid adverse medication outcomes.